All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
How can adherence to treatment be improved in patients with psoriasis and PsA?
By Ella Dixon
During the Psoriasis Hub Steering Committee Meeting in November 2023, key opinion leaders met to discuss adherence to treatment in patients with psoriasis and PsA.
How can adherence to treatment be improved in patients with psoriasis and PsA?
The recorded discussion was chaired by Paolo Gisondi and featured Alice Gottlieb, André Carvalho, Joseph Merola, Laura Coates, and Ulrich Mrowietz. The steering committee discussed why adherence may be lower with certain treatment options and how it can vary across regions. The experts also spoke about difficulties that patients face during treatment and how this impacts adherence.
More about...
Your opinion matters
4 votes - 19 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox